Wesana Health Announces Voting Results of AGSM
10 6월 2023 - 5:48AM
Wesana Health Holdings
Inc. (“
Wesana” or the
“
Company”) (
CSE: WESA; OTCQB:
WSNAF), today announced that all matters put forward at
the Company’s annual general and special meeting (the
“
AGSM”) of shareholders
(“
Shareholders”) held on June 9,
2023 were duly approved by the requisite majority of votes
cast at the AGSM.
AGSM Results
A total of approximately eighty percent (80%) of
the votes entitled by the outstanding shares of the Company were
present and voted at the AGSM by Shareholders and proxyholders. The
following resolutions were approved by over ninety-nine percent
(99%) of votes cast:
- election of all director nominees
to the board of directors for the ensuing year;
- appointment of MNP LLP as the
auditors of the Company for the ensuing year; and
- passing of a special resolution
approving the sale by Wesana Health Inc., a subsidiary of the
Company, of its right and interest in the SANA-013 development
related assets and any other applicable related assets (which may
be a sale of substantially all of the undertaking of the Company)
(the “Transaction”) pursuant to the terms of the
asset purchase agreement among the Company, Lucy Scientific
Discovery Inc. (NASDAQ:LSDI)
(“Lucy”), Lucy Scientific Discovery USA Inc., and
Wesana Health Inc. dated March 20, 2023 (as may be subsequently
amended, supplemented or otherwise modified, the “Asset
Purchase Agreement”) as more particularly described and
set forth in the management information circular of the Company
dated May 9, 2023. The Transaction is expected to close this month
(June 2023), subject to and following the satisfaction (or waiver
as permitted) of the conditions precedent to the Transaction.
ON BEHALF OF THE BOARDDaniel Carcillo, Chairman and Chief
Executive OfficerPhone: 702-329-8038
About Wesana HealthWesana
Health is a data-driven life science company pioneering drug
development through its lead candidate SANA-013. Targeting Major
Depressive Disorder as the lead indication, SANA-013 utilizes
proprietary drug delivery protocols and a novel combination
therapy. Wesana is composed of leaders from the scientific,
research and medical industries driven by a common goal of
improving the lives of millions of people globally suffering from
mental health indications. Learn more at www.wesanahealth.com.
Cautionary Note Regarding
Forward-Looking InformationThis news release contains
“forward-looking information” and “forward-looking statements”
(collectively, “forward looking information”) within the meaning of
applicable securities laws including under the United States
Private Securities Litigation Reform Act of 1995 with respect to
the Transaction, the Company and Lucy, including, but not limited
to: statements relating to the Transaction and the expected terms,
timing and closing of the Transaction, including receipt of
required approvals and satisfaction of other closing conditions,
the anticipated Transaction benefits, including the ability of Lucy
to pursue further research and development related to SANA-013 and
the ability of Lucy to pursue or continue the initiatives that are
underway or contemplated by Lucy, the satisfaction by Lucy of its
obligations under the Asset Purchase Agreement and/or other related
transaction documents, the satisfaction by the Company of its
obligations under the Asset Purchase Agreement and/or other related
transaction documents, and the satisfaction of post-closing
obligations by all applicable parties under the terms of the
Transaction, and any other statement that may predict, forecast,
indicate or imply future plans, intentions, levels of activity,
results, financial position, operational or financial performance
or achievements. Often, but not always, forward-looking information
can be identified by the use of words such as “plans”, “expects”,
“is expected”, “budget”, “scheduled”, “estimates”, “forecasts”,
“intends”, “anticipates”, “will”, “projects”, or “believes” or
variations (including negative variations) of such words and
phrases, or statements that certain actions, events, results or
conditions “may”, “could”, “would”, “might” or “will” be taken,
occur or be achieved. Except for statements of historical fact,
information contained herein constitutes forward-looking
information. Forward-looking information is not a guarantee of
future performance and is based upon a number of expectations and
assumptions of management at the date the statements are made.
Although management believes that the
anticipated future results, performance or achievements expressed
or implied by the forward-looking information are based upon
reasonable assumptions and expectations, the reader should not
place undue reliance on forward-looking information because it
involves assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements to differ materially from anticipated future results,
performance or achievements expressed or implied by such
forward-looking information. Certain risk factors include but are
not limited to the risks associated with the parties’ ability to
satisfy the closing conditions to the completion of the
Transaction; timing of completion of the Transaction, including the
risk that the conditions to the Transaction are not satisfied on a
timely basis or at all and the failure of the Transaction to close
for any other reason; there being no assurance as to the Company’s
ability to continue as a going concern; there being no assurance
that Lucy will have the requisite capital resources to pursue
research and development efforts currently targeted for SANA-013;
there being no assurance that the Company or Lucy will achieve the
results currently targeted for SANA-013; the detrimental impact of
future losses and negative cash flow from operations; requirements
for additional capital; lack of product or service revenue;
research and development of drugs targeting the central nervous
system being particularly difficult; failure to comply with health
and data protection laws and regulations; delays in pre-clinical
and clinical testing resulting in delays in commercializing;
inability to file investigational new drug applications or clinical
trial applications to commence clinical trials in a timely manner;
difficulty enrolling patients in clinical trials; competition from
other biotechnology and pharmaceutical companies; violations of
laws and regulations resulting in repercussions; psychedelic
inspired drugs possibly never being approved as medicines;
regulatory or political change; reliance on third parties to plan,
conduct and monitor preclinical studies and clinical trials;
requirements of commercial scale and quality manufactured drug
supply; negative results from pre-clinical and clinical trials or
studies of others; unfavourable publicity or consumer perception;
not achieving publicly announced milestones; reliance on the
capabilities and experience of key executives and scientists;
disruptions due to acquisitions or collaborations; risk of product
liability claims; COVID-19; litigation; conflicts of interest;
limited operating history; general economic, market and business
conditions and other risk factors, including those found in the
Company’s management discussion and analysis for the years ended
December 31, 2022 and 2021 and the Company’s annual information
form dated September 3, 2021 filed on the Company’s profile on
SEDAR at www.sedar.com and discussed in the Company’s other public
filings available on SEDAR.
Forward-looking information is provided and made
as of the date of this news release and the Company does not
undertake any obligation to revise or update any forward-looking
information other than as required by applicable law.
The Company does not by way of this news release
affirm or adopt any statements, reports or public filings related
or attributed to Lucy in this news release or made by Lucy outside
of this news release.
Lucy Scientific Discovery (NASDAQ:LSDI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lucy Scientific Discovery (NASDAQ:LSDI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024